PCSK9 and Alzheimer disease: ORs for the effects of PCSK9 inhibition on AD risk in the PGC sample ranged from 1.64 (95% CI = 1.17–2.31) per SD lower LDL‐C using allele frequencies from a sample with Finnish ancestry to 1.73 (95% CI = 1.12–2.66) using allele frequencies of samples with ancestries from across Europe.